We are pleased to share the results of a collaborative clinical investigation between Moffitt Cancer Center and the Calcium & Bone Health Institute (CBHI), examining the impact of Sigma Anti-Bonding Calcium (SAC®) on bone mineral density in aging populations.
SAC® calcium, a formulation designed to deliver bioavailable calcium ions without dependence on stomach acid or vitamin D, was evaluated in a 135-subject clinical cohort with varying degrees of bone health status—ranging from normal to osteopenia and osteoporosis.Key findings include:
SAC® calcium, a formulation designed to deliver bioavailable calcium ions without dependence on stomach acid or vitamin D, was evaluated in a 135-subject clinical cohort with varying degrees of bone health status—ranging from normal to osteopenia and osteoporosis.Key findings include:
- Mean bone mineral density increased by 9.4% across the entire cohort.
- Patients with osteopenia and osteoporosis showed statistically significant improvements (p=0.0001).
- Male participants demonstrated greater average gains compared to female participants.
- Improvements were observed across age groups and BMI categories, with overweight and obese participants showing the highest increases.
The T-score and Z-score distributions before and after SAC administration were analyzed using standard DEXA scans, and Speed of Sound (SOS) metrics further confirmed enhanced bone quality.
These findings support SAC® calcium as a promising non-pharmacological intervention for bone health, with particular relevance to oncology patients, aging populations, and individuals with metabolic bone disorders.
These findings support SAC® calcium as a promising non-pharmacological intervention for bone health, with particular relevance to oncology patients, aging populations, and individuals with metabolic bone disorders.
